A5101805079- Biosimilars and Bioanalytical Methods
- Colorectal Cancer Treatments and Studies
- Pharmacogenetics and Drug Metabolism
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pancreatitis Pathology and Treatment
- Pharmaceutical Economics and Policy
- Sarcoma Diagnosis and Treatment
- Organ Donation and Transplantation
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Inflammatory mediators and NSAID effects
- Testicular diseases and treatments
- Drug Transport and Resistance Mechanisms
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Computational Drug Discovery Methods
- Renal and Vascular Pathologies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- IgG4-Related and Inflammatory Diseases
- Esophageal and GI Pathology
- Pharmaceutical studies and practices
- Synthesis and Biological Evaluation
The University of Texas Health Science Center at San Antonio
2024
Hospital Virgen de la Salud
2019-2022
Hospital General de México
2005-2018
Light Prescriptions Innovators (Spain)
2018
Hospital General de Elda
2003-2005
The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and Cmax) between RTXM83, a proposed rituximab biosimilar, its reference product, using population PK model approach.Rituximab PD data were obtained from randomized, double-blind, phase III clinical study (RTXM83-AC-01-11) patients with diffuse large B-cell lymphoma (DLBCL) that received 375 mg/m2 intravenous RTXM83 or product CHOP regimen, every 3 weeks, for six cycles. Rituximab levels...
MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab). To confirm clinical similarity between EU-bevacizumab, a comparability study was undertaken in the first-line treatment of stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC). This multinational, double-blind, randomized, phase III (STELLA) compared or EU-bevacizumab (15 mg/kg) administered with chemotherapy (paclitaxel 200 mg/m2...
Abstract Purpose MB02 is a biosimilar to bevacizumab that has demonstrated similar physicochemical and functional properties in vitro studies the reference (Avastin ® ). This study aims assess pharmacokinetic (PK) similarity of Japanese population. Methods double-blind, randomized, parallel-group, single-dose PK study, was performed healthy male volunteers. Subjects were equally randomized (1:1) receive single (3 mg/kg) IV dose or bevacizumab. assessments done up 70 days post-dose....
We conducted a randomized, crossover study in 23 healthy young female volunteers to compare the bioavailability of two brands meloxicam (7.5 mg) tablets and obtain pharmacokinetic parameters this molecule Mexican population not reported previously. Two (15 were administered as single dose on 2 treatment days separated by 1-week washout period. After dosing, serial blood samples collected for period 72 h. Plasma harvested was analyzed modified validated high-performance liquid chromatography...
To evaluate the bioequivalence between two 250 mg-tablets of lysine clonixinate, Dorixina Forte (Siegfried Rhein, México) as reference product, and Prestodol (Farmaceúticos Rayere, S.A., test formulation.26 healthy adult female Mexican volunteers received a single oral dose 250-mg clonixinate under fasting conditions. The drug was administered following randomized, two-period, two-sequence, cross-over design. Twelve serial blood samples were collected up to 8 h after dosing, clonixin (CLX)...
Background: Patients with spinal cord injury (SCI) are at increased risk of renal insufficiency, so their function must regularly be monitored. Glomerular filtration rate (GFR) assessment is challenging as it requires measuring clearance exogenous markers, which impractical in most clinical settings. Thus, equations have been formulated to estimate GFR that utilize serum creatinine (Cr) or cystatin C (CysC). Objectives: Given loss muscle mass after SCI, we hypothesized using CysC would more...
Aims In 2019 the working group of European Society Gastrointestinal Endoscopy(ESGE) was reunited with objective developing technical and quality standards for small- bowel endoscopy, in order to improve daily practice endoscopy services.
Resumen.-OBJETIVO: Presentar un caso de rabdomiosarcoma paratesticular derecho en adulto joven 21 años edad.MÉTODOS: Tras realizar tratamiento con orquiectomía radical derecha vía inguinal, que se clasifica dentro del grupo clínico IA según el IRS -III (enfermedad localizada completamente resecada), complementa vincristina y actinomicina-D.RESULTADOS/CONCLUSIONES: Encontrándose libre enfermedad a los 18 meses la intervención quirúrgica.Destacando importancia adyuvante evolución posterior tumoral.
<h3>Background</h3> The use of biological treatments for psoriasis involves a significant improvement in disease management. However, the economic impact its on health systems is high. Optimised treatment patterns therapies, clinically controlled patients, attempt to find more efficient these drugs. <h3>Purpose</h3> To analyse patients with an optimised pattern and estimate annual saving third-level hospital. <h3>Material methods</h3> Observational, retrospective longitudinal study treated...